Article: TransMolecular Presents Imaging and Pharmacokinetic Analysis of (131)Iodine-TM601 at Society for Nuclear Medicine Meeting.

CAMBRIDGE, Mass. -- TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the presentation of an imaging and pharmacokinetic analysis of intravenous 131I-TM601 in patients with primary malignant glioma or solid tumor metastases. The abstract was discussed in an oral presentation at the Society for Nuclear Medicine's 55th Annual Meeting on June 16, 2008 by investigators at Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine.

Pharmacokinetic analysis revealed that 131I-TM601 rapidly clears from the blood stream and is then quickly removed from the body through the urinary system. ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!